Incannex Healthcare Inc.
For the period ended Aug 25, 2026. Filed Aug 25, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 25, 2026 · Filed Aug 25, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · DReAMzz Phase 2 Dose-Optimization Study
DReAMzz Phase 2 Dose-Optimization Study
DReAMzz is a Phase 2 crossover dose-optimization study designed to further characterize the dose-response profile of IHL-42X and inform dose selection for subsequent late-stage clinical development.
The study will evaluate objective sleep-related measures alongside patient-reported outcomes, providing additional data intended to refine the IHL-42X treatment regimen and strengthen the design of the Company’s planned Phase 3 program.
Incannex has established a network of 14 clinical trial sites across the United States to support execution of DReAMzz. Drug product has been manufactured, regulatory and operational preparations have been completed, clinical sites have commenced patient screening and the first patient has now been dosed.
About IHL-42X
IHL-42X is Incannex’s proprietary oral fixed-dose combination of dronabinol and acetazolamide being developed for the treatment of obstructive sleep apnea.
The combination is designed to target complementary physiological mechanisms implicated in OSA through a single oral pharmaceutical therapy.
IHL-42X has received Fast Track designation from the U.S. Food and Drug Administration.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.